January 11, 2019
WELLESLEY, Mass, Jan. 11, 2019 – The global brain cancer therapeutics market is thriving, resulting from the rising incidence of brain cancer, early cancer detection, research initiatives, R&D collaborations, an increase in oncology spending and accelerated approvals for drugs used in rare diseases, according to the report “Brain Tumor Therapeutics: Global Markets to 2023.”
The global market for brain tumor therapeutics was valued at $1.1 billion in 2018 and is expected to reach $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 12.9% during the forecast period, according to BCC Research.
“Current therapeutics for brain tumors include chemotherapy, targeted therapy, surgery and radiotherapy,” the report notes. “Many investigational therapies are carried out in advanced human clinical trials. A wide range of immunotherapy drugs, cancer vaccines and successful therapeutics will be developed in the near future. Innovation is expected to result in a surge of market growth in the field.”
Current Trends in the Brain Tumor Therapeutics Market
Current trends in cancer treatment focus on tailoring treatment approaches through molecular biology and genetic understanding of the disease in a particular patient – an approach referred to as personalized medicine. However, in brain tumors, these strategies are currently used as an adjunct to standard treatment protocols and have not yet fully replaced conventional therapy.
Editors/reporters requesting analyst interviews should contact Eric Surber at firstname.lastname@example.org.
Brain Tumor Therapeutics: Global Markets to 2023( PHM208A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.